ADM Tronics Unlimited, Inc.

What they do

ADMT develops and manufactures electronic technologies for non-invasive electrotherapeutic and diagnostic medical devices, including contract manufacturing for non-affiliated customers at its FDA-registered facility in Northvale, NJ. It also develops, manufactures, and sells water-based chemical products for industrial uses through its Antistatic Industries division, acquired in 2009, which makes conductive paints, coatings, floor mats, garments, and tapes. The Company provides research, development, quality control, quality assurance, and regulatory compliance engineering services, recognizing that revenue monthly over time.

Revenue drivers

• Electronics (medical devices and contract manufacturing) — Largest segment, generating $472,990 of revenue in the quarter ended June 30, 2026, with gross profit percentage of 56%. Backlog for electronic product orders was approximately $956,000 as of March 31, 2026.
• Chemical products (industrial, medical, cosmetic) — Second-largest segment, with $325,860 of revenue and a 29% gross profit percentage in the quarter ended June 30, 2026; includes water-based primers, adhesives, coatings, resins, additives, and antistatic products.
• Engineering services — Smallest segment, with $67,405 of revenue in the quarter ended June 30, 2026, and the highest gross margin at 51%; recognized monthly as performance obligations are satisfied.

Recent performance

For the three months ended June 30, 2026, total revenue was $866,255, down $107,420 from $973,675 in the same quarter of 2025, with declines in all three segments. Gross profit fell to $395,050 from $481,293, and total operating income was a loss of $20,655 versus income of $109,234 a year earlier. Other income of $55,019 offset part of the operating loss, leaving income before income taxes of $34,364, compared to $329,134 in the prior-year quarter. Annual revenue has moved between $3.0M and $3.7M over fiscal 2022 through 2026, and net losses were $877,222 in fiscal 2024, $123,056 in fiscal 2025, and $100,374 in fiscal 2026.

Strategy

The Company states it has increased internal research and development by using its engineering resources to advance its own proprietary medical device technologies. Its Antistatic Industries division continues to invest in research and development to enhance existing products and develop new solutions for static control and manufacturing process efficiency. Management also cites expansion of its medical device design and engineering capabilities as a way to expand revenue potential. Sonotron Medical Systems, Inc., a former inactive subsidiary, was dissolved during fiscal 2026 with no material impact.

Risks

• Environmental and regulatory compliance costs — ADMT is subject to federal, state, and local laws governing air and water discharges, hazardous substances, and workplace safety, and new or stricter requirements could increase operating costs.
• Declining quarterly revenue — Total revenue in the quarter ended June 30, 2026, fell to $866,255 from $973,675 in the prior-year period, with all three segments lower.
• Reliance on contract manufacturing and a small customer base — The electronics segment depends on contract manufacturing for non-affiliated customers, and as of March 31, 2026, electronic product backlog was approximately $956,000.
• Thin margins and recurring losses — ADMT reported net losses in each of fiscal 2024, 2025, and 2026, including $100,374 in fiscal 2026, and chemical segment gross margin fell to 29% in the June 2026 quarter.

Outlook

Management states it expects continued growth in medical device engineering activities and that expanded design and engineering capabilities should enable it to expand revenue potential. The Company's operating plan includes initiatives to expand market presence and penetration, and it says it is pursuing new technology opportunities that could increase revenues. These statements are forward-looking and subject to risks and uncertainties described in its filings.